Page last updated: 2024-12-08

sodium salicylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID16760658
CHEMBL ID447868
CHEBI ID9180
SCHEMBL ID4603
MeSH IDM0020117

Synonyms (116)

Synonym
benzoic acid, 2-hydroxy-, monosodium salt
salicylic acid, sodium salt
SPECTRUM5_001120
einecs 200-198-0
ccris 6715
natrium salicylat [german]
nsc 202167
monosodium 2-hydroxybenzoate
enterosalicyl
idocyl novum
C07587
54-21-7
sodium salicylate ,
sodium salicylate, meets usp testing specifications
sodium salicylate, reagentplus(r), >=99.5%
salisod
nadisal
enterosalil
sodium 2-hydroxybenzoate
neo-salicyl
salicylate, sodium
nsc-202167
sodium o-hydroxybenzoate
aroall
kerosal
diuretin
nsc202167
o-hydroxybenzoic acid, sodium salt
magsalyl
salsonin
glutosalyl
kerasalicyl
alysine
parbocyl-rev
entrosalyl
clin
monosodium salicylate
sodium salicylate (jp17/usp)
D00566
NCGC00094780-02
NCGC00094780-01
KBIOGR_001429
KBIO3_001820
SPBIO_002009
SPECTRUM3_000900
SPECTRUM2_001945
SPECTRUM4_000995
SPECTRUM1500533
sodium salicylate, puriss. p.a., >=99.5% (nt)
HMS2092G17
CHEMBL447868
salicylate sodium
salicylic acid sodium salt
chebi:9180 ,
natrii salicylas
natrum salicylicum
AKOS005766021
HMS1920P16
AKOS003051698
tox21_200411
dtxcid701708
dtxsid5021708 ,
cas-54-21-7
NCGC00257965-01
90218-94-3
CCG-39474
natrium salicylat
wiq1h85syp ,
ec 200-198-0
sodium salicylate [usp:jan]
unii-wiq1h85syp
FT-0631235
benzoic acid, 2-hydroxy-, monosodium salt, coupled with 4-amino-1-naphthalenesulfonic acid and diazotized 2-(4-aminophenyl)-1h-benzimidazol-5-amine, sodium salt
90218-97-6
salicylic acid sodium salt [mi]
salicylate sodium [who-dd]
sodium salicylate [who-ip]
sodium salicylate [inci]
sodium salicylate [vandf]
sodium salicylate [mart.]
sodium salicylate [usp-rs]
natrum salicylicum [hpus]
sodium salicylate [usp monograph]
sodium salicylate [jan]
natrii salicylas [who-ip latin]
sodium salicylate [ep monograph]
CS-2008
HY-B0167A
SCHEMBL4603
ABBQHOQBGMUPJH-UHFFFAOYSA-M
2,4-dimethoxyphenylboronicacid,pinacolester
mfcd00002440
sodium salicylate, tested according to ph.eur.
sodium salicylate, 99%
sodium salicylate, united states pharmacopeia (usp) reference standard
sodium salicylate, saj first grade, >=99.5%
sodium salicylate, saj special grade, >=99.5%
salicylic acid sodium
sodium salicylate, p.a., 99.5%
sodium salicylate, vetec(tm) reagent grade, 99%
sodium salicylate, european pharmacopoeia (ep) reference standard
salicylic acid sodium salt;2-hydroxybenzoic acid sodium salt
Q414547
sodium;2-hydroxybenzoate
D83111
sodium;2-carboxyphenolate
sodium salicylate (usp-rs)
saligard 60
sodium salicylate (mart.)
pro-prin
sodium salicylate (usp monograph)
sodium salicylate (ep monograph)
uni-sol 60
uni-sol
sodium salicylate (usp:jan)
benzoic acid,2-hydroxy-,monosodium salt,coupled with 4-amino-5-hydroxy-2,7-naphthalenedisulfonic acid,diazotized 2-(4-aminophenyl)-1h-benzimidazol-5-amine and diazotized 4-nitrobenzenamine,sodium

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Instead of using death as the principal criterion of toxicity, it is based on a careful, standardized clinical assessment of toxic signs measured in the nonlethal dose range."( Acute toxicity testing in the nonlethal dose range: a new approach.
Sigg, H; Tamborini, P; Zbinden, G, 1990
)
0.28
" A marked increase in fetal adverse effects was observed at analgetic doses with the once-a-day bolus regimen compared to the constant rate input."( Constant rate of infusion--improvement of tests for teratogenicity and embryotoxicity.
Blomquist, I; Gabrielsson, J; Larsson, S; Paalzow, L, 1985
)
0.27
"We studied the enhancing and toxic effects of five different absorption enhancers on the transport of FITC-dextran with an average molecular weight of 4000 (FD-4) across Caco-2 cell monolayers, and their enhancing effects were also compared with those in rat intestine."( Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers.
Fujita, T; Hattori, K; Lundborg, E; Murakami, M; Muranishi, S; Quan, YS; Yamamoto, A, 1998
)
0.3
"rad;OH concentration in embryonic tissues after COC exposure and toxic interactions of COC and NaSAL can also occur at an earlier stage of development."( Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.
Sparber, SB; Venturini, L, 2001
)
0.31
" Acetylsalicylic acid (ASA) and sodium salicylate (SS) are considered safe for poultry and often used in avian medicine."( Adverse effects associated with high-dose acetylsalicylic acid and sodium salicylate treatment in broilers.
Bobrek, K; Dzimira, S; Graczyk, S; Poźniak, B; Switała, M, 2012
)
0.38
" Even without a clear synergistic interaction, the combination of DHA and SS provides a safe and affordable form of cancer treatment."( Additive cytotoxic effects of dihydroartemisinin and sodium salicylate on cancer cells.
Singh, NP; Wickerath, M, 2014
)
0.4
" Since formulations containing PQ and salicylates have been proposed, these results point that the stoichiometry of 1:4 (PQ:salicylates) should be considered to optimize prevention of PQ-mediated toxic effects."( Decreasing the toxicity of paraquat through the complexation with sodium salicylate: Stoichiometric analysis.
Afonso, CM; Amorim, R; Carvalho, F; Dinis-Oliveira, RJ; Gales, L, 2015
)
0.42
" The underlying source of these side effects include the generation of reactive oxygen species which are toxic and damaging to tissues and organs."( Prophylactic consequences of sodium salicylate nanoparticles in cisplatin-mediated hepatotoxicity.
Alkhalaf, M; El-Toukhy, SE; Mohamed, NA, 2023
)
0.91

Pharmacokinetics

The aim of the study was to compare drug effects on biomarkers of pain and distress following sham and actual castration and dehorning. sodium salicylate did not show any marked change in the pharmacokinetic parameters during a stressful situation.

ExcerptReferenceRelevance
" Excretion of salicylates in old rats was delayed compared to that in adult ones, the half-life in old rats was 2--3 times as long as that in adult species."( [Pharmacokinetic characteristics of salicylates in old animals].
Bezverkhaia, IS,
)
0.13
" On the other hand, sodium salicylate did not show any marked change in the pharmacokinetic parameters during a stressful situation."( Effect of stress on the pharmacokinetics of sodium salicylate and quinidine sulphate in rats.
Otto, U; Paalzow, L, 1975
)
0.25
" Plasma concentrations of the drugs were determined by validated high-performance liquid chromatography methods and pharmacokinetic parameters were calculated."( Comparative pharmacokinetics of three non-steroidal anti-inflammatory drugs in five bird species.
Baert, K; De Backer, P, 2003
)
0.32
"The pharmacodynamic properties of tepoxalin, Na-salicylate and ketoprofen were determined in an intravenous lipopolysaccharide (LPS) inflammation model in broiler chickens."( Pharmacodynamics of tepoxalin, sodium-salicylate and ketoprofen in an intravenous lipopolysaccharide inflammation model in broiler chickens.
Beyaert, R; Croubels, S; de Backer, P; de Baere, S; de Boever, S; Meyer, E; Neirinckx, EA, 2010
)
0.36
"To determine the pharmacokinetic parameters of xylazine, ketamine, and butorphanol (XKB) administered IM and sodium salicylate (SAL) administered PO to calves and to compare drug effects on biomarkers of pain and distress following sham and actual castration and dehorning."( Pharmacokinetics and physiologic effects of intramuscularly administered xylazine hydrochloride-ketamine hydrochloride-butorphanol tartrate alone or in combination with orally administered sodium salicylate on biomarkers of pain in Holstein calves followi
Baldridge, SL; Coetzee, JF; Dritz, SS; Gehring, R; Havel, J; Kukanich, B; Reinbold, JB, 2011
)
0.37
" Plasma drug concentrations were determined using high-performance liquid chromatography with ultraviolet detection and pharmacokinetic variables were calculated using a non-compartmental model."( Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys.
Jaworski, K; Niewiński, P; Okoniewski, P; Poźniak, B; Świtała, M, 2013
)
0.39
" On the 1st, 7th and 14th d a 24 h-long pharmacokinetic study was carried out, whereas eggs were collected daily."( Pharmacokinetics of repeated sodium salicylate administration to laying hens: evidence for time dependent increase in drug elimination from plasma and eggs.
Bobrek, K; Bobusia, K; Gaweł, A; Grabowski, T; Motykiewicz-Pers, K; Poźniak, B; Rak, L; Świtała, M, 2015
)
0.42
" Plasma drug concentrations were assessed by high-performance liquid chromatography, and pharmacokinetic parameters were calculated by noncompartmental analysis."( The influence of rapid growth on sodium salicylate pharmacokinetics in male turkeys.
Grabowski, T; Motykiewicz-Pers, K; Poźniak, B; Świtała, M, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"Minimum bactericidal concentrations of salicylate, nicotinaldehyde singly, and in combination with nicotinic acid, or nicotinamide were determined for Staphylococcus aureus 79 and 80, and Escherichia coli 95, at inocula of 10(7)--10(2)."( The sensitivity of Staphylococcus aureus 79 and 80, and Escherichia coli 95 to sodium salicylate, nicotinaldehyde singly, and in combination with nicotinic acid or nicotinamide.
Kaplan, D, 1979
)
0.26
" We investigated whether salicylate and aspirin interact in platelets in humans at doses and plasma levels of clinical relevance."( Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function.
Bonati, M; Cerletti, C; de Gaetano, G; Dejana, E; del Maschio, A; Galletti, F; Tognoni, G, 1984
)
0.27
" All these drugs therefore appear to interact with the same site on platelet cyclo-oxygenase."( Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclo-oxygenase. Evidence from "in vivo" drug interaction studies in rats.
Cerletti, C; De Gaetano, G; Livio, M, 1982
)
0.26

Bioavailability

Sodium salicylate improves the rectal absorption of drugs which exhibit molecular self-association. The bioavailability and pharmacokinetics of salicylic acid (SA) were studied after single and multiple doses.

ExcerptReferenceRelevance
"Experimental study of absorption, distribution, metabolism and excretion of salicylic acid and salicylate upon ageing showed that the sodium salicylate absorption rate is considerably decreased in old rats and rabbits."( [Pharmacokinetic characteristics of salicylates in old animals].
Bezverkhaia, IS,
)
0.13
" However, GM absorption was marked when 90 mg of solid SA or CA was added (the bioavailability of GM was 58% with SA, and 59% with CA)."( Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate.
Matsumoto, M; Matsumoto, Y; Murakami, C; Murakoshi, R; Tojima, T; Watanabe, Y, 1989
)
0.28
" The results obtained here, together with our previously reported data, indicate that the interference between sodium salicylate and drug self-association behavior, by increasing drug solubility, may substantially contribute to the improved drug bioavailability mediated by salicylate."( Prevention of molecular self-association by sodium salicylate: effect on insulin and 6-carboxyfluorescein.
Alhaique, F; Fisher, P; Memoli, A; Riccieri, FM; Santucci, E; Touitou, E, 1987
)
0.27
"Sodium salicylate improves the rectal absorption of drugs which exhibit molecular self-association; it is suggested that salicylate may improve drug bioavailability by altering the drug self-association pattern."( Prevention of molecular self-association by sodium salicylate: effect on methylene blue.
Fisher, P; Touitou, E, 1986
)
0.27
" The presence of sodium salicylate and a nonionic surface-active agent, Brij 35, gave increased bioavailability as high as 20% compared with 3% for a system without adjuvants."( Use of adjuvants for enhancement of rectal absorption of cefoxitin in humans.
Burnham, WR; Davis, SS; O'Brien, J; Wilson, P, 1985
)
0.27
" The microcapsules showed no decrease in bioavailability and only slight faecal blood loss during acute toxicity testing for gastrointestinal bleeding."( In vitro and in vivo evaluation of cellacephate microcapsules of sodium salicylate prepared by pan coating.
Deasy, PB; O'Connell, MJ,
)
0.13
" Microenema formulations containing 4% gelatin showed the highest insulin bioavailability of the formulations studied whereas microenemas (without gelatin) and suppository formulations were not as effective in enhancing the rectal absorption of insulin."( Enhancement of rectal absorption of insulin using salicylates in dogs.
Caldwell, L; Higuchi, T; Kamada, A; Nishihata, T; Routh, M; Rytting, JH, 1983
)
0.27
"The bioavailability and pharmacokinetics of salicylic acid (SA) were studied after single and multiple doses of a new slow-release formulation, based on porous membrane diffusion of sodium salicylate (NaSA)."( In vitro and in vivo evaluation of controlled-release and enteric-coated formulations of sodium salicylate.
Borgström, L; Ekman, B; Larsson, H; Leden, I; Lindahl, A; Melander, A; Wåhlin-Boll, E,
)
0.13
" The increased gentamicin bioavailability in response to sodium salicylate adjuvant activity appeared to be independent of and additive to the increased gentamicin absorption due to high ionic strength conditions."( Influence of ionic strength on rectal absorption of gentamicin sulfate in the presence and absence of sodium salicylate.
Caldwell, LJ; Fix, JA; Leppert, PS; Porter, PA, 1983
)
0.27
" Because the bioavailability of salicylate was complete, salicylate was given orally in all subsequent experiments."( Sex differences in absorption kinetics of sodium salicylate.
Miaskiewicz, SL; Shively, CA; Vesell, ES, 1982
)
0.26
" Neither differences in bioavailability of ASA nor the formation of SA seems to contribute to the aspirin-elicited reactions."( Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects.
Anderson, P; Andersson, R; Boréus, LO; Dahlén, B; Zetterström, O, 1994
)
0.29
" sucrose, aluminium stearate, Cab-o-sil, hydrogenated castor oil and lecithin, either alone or in combination, on the bioavailability of sodium salicylate from suspension in fractionated coconut oil have been investigated using the rabbit as the test animal."( Effects of excipients on the bioavailability of sodium salicylate from orally administered, oily suspensions.
al-Hammami, OM; Richards, JH, 1996
)
0.29
" From the values of K beta-CD:SA- = (105 +/- 15)M-1 and KDIMEB:SA- = (140 +/- 20)M-1 obtained, the bioavailability of the salicylate drug in the complexed form has been discussed."( Binding of sodium salicylate by beta-cyclodextrin or 2,6-di-O-methyl-beta-cyclodextrin in aqueous solution.
Aicart, E; Junquera, E; Peña, L, 1998
)
0.3
"Oral bioavailability of biologically active peptides and proteins is generally very low because they are extensively degraded by peptidases and proteases in the gastrointestinal tract and impermeable through the intestinal mucosal membrane."( [Methodologies for regulation of intestinal absorption of biologically active peptides].
Fujita, T; Muranishi, S, 1998
)
0.3
"The purpose of this work is to develop a thermo-reversible insulin liquid suppository, which undergoes a phase transition to bioadhesive gels at body temperature and enhances the bioavailability of insulin."( Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement.
Choi, H; Jung, J; Kim, C; Yun, M, 1999
)
0.3
"The need to develop chloroquine suppository formulations that yield optimal bioavailability of the drug has been emphasized."( Effects of absorption enhancers in chloroquine suppository formulations: I. In vitro release characteristics.
Adebayo, AS; Babalola, CP; Onyeji, CO, 1999
)
0.3
" The formulation was tested to determine its bioavailability enhancement in a non-flush/non-ligated rat ileal model."( Enhanced ileal absorption of a hydrophilic macromolecule, pentosan polysulfate sodium (PPS).
Dong, L; Nguyen, J; Wong, P; Yum, A, 2004
)
0.32
" peak concentration (c(max)); peak time (t(max)); area under the curve (AUC); elimination rate constant (k); absorption rate constant (k(a)); Drug clearance (cl(t)), and the volume of distribution (v(d)) of sodium salicylate administered in fractionated coconut oil (FCO) have been compared with that from an aqueous and glycerin vehicles using a three-way crossover study in 12 rabbits."( Biopharmaceutic and pharmacokinetic studies following the oral administration of sodium salicylate in oily and aqueous vehicles to rabbit.
Alhamami, OM; Aljanabi, NH; Shalan, NM, 2006
)
0.33
"The effect of delay in gastric emptying rate (GER) caused by oil on the bioavailability of sodium salicylate was investigated."( Delay in gastric emptying rate enhances bioavailability of sodium salicylates in rabbit.
Alhamami, OM, 2007
)
0.34
" The pH-dependent release of PTX from HP micelles can be used to increase the bioavailability of PTX upon oral delivery."( Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel.
Acharya, G; Huh, KM; Kim, JY; Kim, S; Park, K, 2008
)
0.35
" The bioavailability of SS was complete and the maximal plasma concentration of SA (C max) after oral administration was 96."( Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys.
Jaworski, K; Niewiński, P; Okoniewski, P; Poźniak, B; Świtała, M, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" The knowledge of this fact is of great importance, and should be taken into consideration in the calculation of proper dosage of various drugs in the newborns and infants."( [Binding capacity of some drugs to plasma proteins of newborns in comparison with adults (author's transl)].
Bozkowa, K; Hofman, H; Piekarczyk, A; Prokopczyk, J; Wańkowicz, B, 1977
)
0.26
"Acute inflammation was induced in rats by subcutaneous implantation of plastic sponges, and the penetration of salicylate and naproxen into the inflammatory exudate was studied after oral dosing with these compounds."( Penetration of naproxen and salicylate into inflammatory exudates in the rat.
Anttila, M; Dean, PB; Doherty, NS, 1977
)
0.26
"91 hours) of orally administered aspirin and rapid elimination (biologic half-life, 32 minutes) of salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate concentration greater than 30 mug/ml, which was considered to be therapeutically effective."( Pharmacokinetics and dosage of aspirin in cattle.
Baggot, JD; Gingerich, DA; Yeary, RA, 1975
)
0.25
" The theoretical model and experimental results showed good agreement and indicated that this type of matrix geometry may be useful as a pharmaceutical dosage form to approximate zero-order release."( Solute release from a porous polymeric matrix: inwardly tapered disk with a central releasing hole.
Béchard, S; McMullen, JN, 1988
)
0.27
" Intraperitoneal dosing of salicylate resulted after approximately 4 h in similar vascular and extravascular drug concentrations."( The cellular association of sodium salicylate and indomethacin in peritoneal fluid of ascites bearing mice.
Huisman, JA; Raghoebar, M; van den Berg, WB; van Ginneken, CA, 1987
)
0.27
" after dosing but showed a partial recovery at the 4hr."( Nicotinamide-adenine dinucleotides in acute liver injury induced by ethionine, and a comparison with the effects of salicylate.
Sawyer, BC; Slater, TF, 1966
)
0.24
" Changes in the distribution of ATP between the cell sap and the large-particle fraction were determined at intervals after rats had been dosed with various substances."( Liver adenosine triphosphate content and bile flow rate in the rat.
Delaney, VB; Slater, TF, 1970
)
0.25
" These approaches include (1) to use additives such as absorption enhancers and protease inhibitors, (2) to modify the peptide molecules to produce prodrugs and analogs, (3) to develop an administration method for peptides that can serve as an alternative to oral and injection administration and (4) to use the dosage forms to these peptide drugs."( [Methodologies for regulation of intestinal absorption of biologically active peptides].
Fujita, T; Muranishi, S, 1998
)
0.3
" Novel features of the model included oral dosing of salicylate, test stimuli that included a range of pure tones and silence, and assessment of tinnitus for several months."( Behavioral model of chronic tinnitus in rats.
Bauer, CA; Boley, J; Brozoski, TJ; Rojas, R; Wyder, M, 1999
)
0.3
" The relationship between cell number and optical density is linear, and there is a close correlation between the dose-response curves generated by this method and alternative isotopic detection methods and cell counting."( Scintillation autofluorographic assessment of isotope uptake in human glioma cells grown on microtitration plates using sodium salicylate.
Darling, JL; Thomas, DG, 2000
)
0.31
" Choice of drug and of dosage is usually empirical, since studies of anti-inflammatory drugs are lacking."( Comparative pharmacokinetics of three non-steroidal anti-inflammatory drugs in five bird species.
Baert, K; De Backer, P, 2003
)
0.32
"This study evaluated and optimised the ninhydrin assay as a tool for measuring the in vitro release and dissolution of chitosan from solid dosage forms."( Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms.
Illum, L; Leane, MM; Nankervis, R; Smith, A, 2004
)
0.32
"Cellulose ethers have been increasingly used in the formulation of controlled release dosage forms; among them, compressed hydrophilic matrices for the oral route of administration are of special importance."( Towards elucidation of the drug release mechanism from compressed hydrophilic matrices made of cellulose ethers. I. Pulse-field-gradient spin-echo NMR study of sodium salicylate diffusivity in swollen hydrogels with respect to polymer matrix physical stru
Doelker, E; Ferrero, C; Jeannerat, D; Massuelle, D, 2008
)
0.35
"001), and although PTS was reduced in the 25 and 75 mg/kg SAL dosage groups compared to the saline group, only the 75 mg/kg SAL group was significantly different at all but 2 kHz frequency."( Dosing study on the effectiveness of salicylate/N-acetylcysteine for prevention of noise-induced hearing loss.
Coleman, J; Huang, X; Jackson, R; Kopke, R; Liu, J,
)
0.13
" Facilitation of osteoblast apoptosis occurred regardless of IND dosage under hypoxic conditions."( Facilitation of human osteoblast apoptosis by sulindac and indomethacin under hypoxic injury.
Chang, CH; Chen, YC; Fan, SC; Huang, CH; Liu, C; Tsai, AL; Wu, CC, 2012
)
0.38
"This study investigated a sieve classification method for evaluating carrier materials and particle size fractions, which could be a valuable tool in the early development of pharmaceutical dosage forms containing low-dose interactive mixtures."( Evaluation of a sieve classification method for characterization of low-dose interactive mixtures.
Bredenberg, S; Dahlgren, A; Mattsson, S,
)
0.13
" When applying this dosing regimen, SS showed minimal (if any) efficacy while DX, alone or in combination with SS, substantially aggravated the emerging lung edema (lung weights) with 40% mortality."( Single high-dose dexamethasone and sodium salicylate failed to attenuate phosgene-induced acute lung injury in rats.
Liu, F; Pauluhn, J; Trübel, H; Wang, C, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Salicylate-Sodium Action Pathway2967

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
acetylcholinesteraseHomo sapiens (human)Potency64.70860.002541.796015,848.9004AID1347395
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID355030Antiinflammatory activity against carrageenan-induced rat edema assessed as inhibition of paw edema at 200 mg/kg after 3 hrs1996Journal of natural products, Jun, Volume: 59, Issue:6
Isolation of two new antiinflammatory biflavanoids from Sarcophyte piriei.
AID476042Reduction of viologen poisoning in Wistar rat assessed as 125 mg/kg viologen-associated mortality rate at 200 mg/kg, ip after 30 days2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Highly effective binding of viologens by p-sulfonatocalixarenes for the treatment of viologen poisoning.
AID476041Reduction of viologen poisoning in Wistar rat assessed as 25 mg/kg viologen-associated mortality rate at 200 mg/kg, ip after 30 days2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Highly effective binding of viologens by p-sulfonatocalixarenes for the treatment of viologen poisoning.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,847)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901215 (65.78)18.7374
1990's205 (11.10)18.2507
2000's234 (12.67)29.6817
2010's156 (8.45)24.3611
2020's37 (2.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials50 (2.46%)5.53%
Reviews25 (1.23%)6.00%
Case Studies10 (0.49%)4.05%
Observational0 (0.00%)0.25%
Other1,946 (95.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Salsalate on Prandial-Induced Vascular Inflammation After SCI [NCT01201759]18 participants (Actual)Interventional2009-07-31Completed
Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome [NCT01489319]Phase 147 participants (Actual)Interventional2012-02-29Terminated(stopped due to The PI left Indiana University. The findings served as preliminary data for a recently awarded NIH R01 grant.)
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD) [NCT00624923]Phase 2/Phase 3340 participants (Actual)Interventional2008-09-30Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate [NCT00799643]Phase 2/Phase 3638 participants (Actual)Interventional2008-11-30Completed
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease [NCT04146038]Phase 25 participants (Actual)Interventional2020-10-26Completed
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study) [NCT01775865]Phase 259 participants (Actual)Interventional2012-09-30Completed
Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls [NCT00837590]Phase 116 participants (Actual)Interventional2009-03-31Terminated(stopped due to Preliminary results indicated no measurable benefit.)
A Phase I Study of Salicylate for Adult Patients With Advanced Myelodysplastic Disorders or Acute Myelogenous Leukemia [NCT00004245]Phase 10 participants Interventional1999-08-31Completed
A Pilot Study to Determine the Effects of 12 Weeks of Treatment With Salsalate on Measures of Peripheral Neuropathy in Type 1 Diabetes [NCT01480297]Phase 28 participants (Actual)Interventional2011-11-30Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate [NCT00392678]Phase 2/Phase 3277 participants (Actual)Interventional2006-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00392678 (7) [back to overview]Change From Baseline and Trends in Fasting Glucose Over Time
NCT00392678 (7) [back to overview]Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index
NCT00392678 (7) [back to overview]Change in HbA1c
NCT00392678 (7) [back to overview]Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1
NCT00392678 (7) [back to overview]Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index
NCT00392678 (7) [back to overview]Safety and Tolerability
NCT00392678 (7) [back to overview]Change in Lipids
NCT00624923 (4) [back to overview]Change in Cholesterol
NCT00624923 (4) [back to overview]Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT
NCT00624923 (4) [back to overview]Change in Inflammation Marker: CRP
NCT00624923 (4) [back to overview]Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months
NCT00799643 (2) [back to overview]Change From Baseline in Fasting Glucose Over Time.
NCT00799643 (2) [back to overview]The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.
NCT00837590 (1) [back to overview]Vascular Function
NCT01201759 (4) [back to overview]Change in Area Under the Curve (AUC) for Glycemia (Glucose) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.
NCT01201759 (4) [back to overview]Change in Area Under the Curve (AUC) for Lipemia (Free Fatty Acids ) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.
NCT01201759 (4) [back to overview]Change in Area Under the Curve (AUC) for Lipemia (Triglycerides) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.
NCT01201759 (4) [back to overview]Change in Fasting Values for Vascular Inflammation IL-6 at Visits 2-3 or 4-5
NCT01480297 (1) [back to overview]Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm
NCT01775865 (2) [back to overview]Brachial Artery Flow-mediated Dilation (FMD)
NCT01775865 (2) [back to overview]Carotid-femoral Pulse Wave Velocity (CFPWV)
NCT04146038 (2) [back to overview]Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine
NCT04146038 (2) [back to overview]Number of Participants With Complete or Partial Response
[back to top]

Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14

Interventionpmol/l (Median)
Placebo-3.0
Salsalate 3.0 g/d15
Salsalate 3.5 g/d7.6
Salsalate 4.0 g/d27

[back to top]

Change in HbA1c

Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week

Intervention% HbA1c (Mean)
Placebo0
Salsalate 3.0 g/d-0.4
Salsalate 3.5 g/d-0.3
Salsalate 4.0 g/d-0.5

[back to top]

Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1

The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week

Intervention% (units of HbA1c) (Mean)
3.0 g/d-0.36
3.5 g/d-0.34
4.0 g/d-0.49
Placebo-0.01

[back to top]

Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14

InterventionC-peptide in nmol/l (Mean)
Placebo0.10
Salsalate 3.0 g/d-0.07
Salsalate 3.5 g/d-0.03
Salsalate 4.0 g/d0.03

[back to top]

Safety and Tolerability

See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks

Interventionparticipants (Number)
Salsalate 3.0 g/d17
Salsalate 3.5 g/d16
Salsalate 4.0 g/d16
Placebo14

[back to top]

Change in Lipids

"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week

,,,
Interventionmg/dl (Mean)
CholesterolHDLLDLTGTotal to HDL ratio
Placebo000150
Salsalate 3.0 g/d8315-340.1
Salsalate 3.5 g/d-113-22-0.1
Salsalate 4.0 g/d628-160.2

[back to top]

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Interventionmg/dL (Mean)
1- Active Pharmacologic5.1
2- Placebo2.0

[back to top]

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

InterventionU/L (Mean)
1- Active Pharmacologic-1.1
2- Placebo-0.6

[back to top]

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Interventionmg/L (Mean)
1- Active Pharmacologic-0.1
2- Placebo-0.1

[back to top]

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Interventionmm^3 (Mean)
1- Active Pharmacologic0
2-Placebo0

[back to top]

Change From Baseline in Fasting Glucose Over Time.

(NCT00799643)
Timeframe: 48 weeks from baseline

Interventionmg/dl (Mean)
Placebo2.0
Salsalate-13.1

[back to top]

The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.

HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline

InterventionHbA1c units are % (Mean)
Placebo-0.04
Salsalate-0.33

[back to top]

Vascular Function

The primary endpoints of interest is flow-mediated vasodilation (NCT00837590)
Timeframe: Measured at baseline and after a single oral dose of salsalate (Acute) or 2 months' treatment with salsalate (Chronic)

,,
Interventionml/min (Mean)
BaselineSalsalate
Acute Salsalate5.45.6
Chronic Salsalate - Lean8.37.5
Chronic Salsalate - Obese6.74.4

[back to top]

Change in Area Under the Curve (AUC) for Glycemia (Glucose) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.

"The postprandial glycemia is assessed by the change in the AUC for plasma glucose sampled before and after intervention at time points of 0 (immediately post-feeding) to 480 min.~For peak Glucose, and Glucose area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors." (NCT01201759)
Timeframe: Blood samples for each visit were sampled at 0 (immediately post-feeding), and 30,60,90,120,240,360,480 min post-feeding..

Interventionmg*min/dL (Mean)
Placebo1
Salsalate-8

[back to top]

Change in Area Under the Curve (AUC) for Lipemia (Free Fatty Acids ) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.

"The postprandial lipemia is assessed by the change in the AUC for plasma Free fatty acids (FFA)sampled before and after intervention at time points of 0min immediately post feeding to 480 min.~For peak FFA area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors." (NCT01201759)
Timeframe: Each visit sampled at 0 (immediately post-feeding), and 30,60,90,120,240,360,480 min post-feeding..

Interventionmg*min/dL (Mean)
Placebo8
Salsalate-111

[back to top]

Change in Area Under the Curve (AUC) for Lipemia (Triglycerides) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.

"The postprandial lipemia is assessed by the change in the AUC for plasma triglycerides sampled before and after intervention at time points 0 (immediately post-feeding)to 480 min.~For peak TG, and TG area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors." (NCT01201759)
Timeframe: Each visit samples at 0 (immediately post-feeding), and 30,60,90,120,240,360,480 min post-feeding..

Interventionmg*min/dL (Mean)
Placebo-34
Salsalate-62

[back to top]

Change in Fasting Values for Vascular Inflammation IL-6 at Visits 2-3 or 4-5

"The pro-atherogenic inflammatory mediators are assessed by the change in fasting values of Interleukin-6 in plasma concentration Pre and Post intervention at -30 min ( fasting).~For fasting values treatments (placebo and salsalate) and visits (pre and post) were defined as within subject's factors." (NCT01201759)
Timeframe: Study visit at min -30 (fasting)

,
Interventionmg/dL (Mean)
Pre-InterventionPost-Intervention
Placebo0.480.50
Salsalate0.510.19

[back to top]

Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm

Intra-epidermal Nerve Fiber Density (IENFD) was measured at two anatomic locations (thigh and ankle) at baseline and after 12 weeks of treatment with Salsalate. IENFD is expressed as fibers per mm. Means and standard deviations are shown. (NCT01480297)
Timeframe: Baseline and 12 weeks

Interventionfibers per mm (Mean)
Baseline Thigh IENFD(fibers per mm)Baseline Ankle IENFD(fibers per mm)12 Week Thigh IENFD(fibers per mm)12 Week Ankle IENFD(fibers per mm)
Salsalate6.33.05.23.0

[back to top]

Brachial Artery Flow-mediated Dilation (FMD)

Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks

,,
InterventionPercent dilation (Mean)
Baseline4 Weeks
Placebo3.572.50
Salsalate3.494.60
Young Control Group5.88NA

[back to top]

Carotid-femoral Pulse Wave Velocity (CFPWV)

Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks

,,
Interventioncm/sec (Mean)
Baseline4 weeks
Placebo785.1740.01
Salsalate831.3839.6
Young Control Group538.0NA

[back to top]

Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine

Study drug associated adverse events during therapy (NCT04146038)
Timeframe: During the first 2 cycles, 56 days total

InterventionParticipants (Count of Participants)
Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)1

[back to top]

Number of Participants With Complete or Partial Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT04146038)
Timeframe: During the first 2 cycles 56 days total

InterventionParticipants (Count of Participants)
Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)1

[back to top]